市場調査レポート
商品コード
1064773
注意欠陥多動性障害治療薬の世界市場:2021年~2027年Attention Deficit Hyperactivity Disorder Drug Market 2021-2027 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
注意欠陥多動性障害治療薬の世界市場:2021年~2027年 |
出版日: 2022年02月01日
発行: Orion Market Research
ページ情報: 英文 121 Pages
納期: 2~3営業日
|
世界の注意欠陥多動性障害治療薬の市場規模は、予測期間中に大幅なCAGRで拡大すると予測されています。新生児の早産児数の増加が、同市場の成長に寄与しています。メリーランド大学医療センター(UMMC)によると、この病気は現在、早産児の20%が罹患しています。世界中の政府は、注意欠陥多動性障害(ADHD)を含む数多くの精神障害に苦しむ人々の増加に注目しています。このような疾病の治療に対する政府の関心は、世界市場をさらに牽引するものと思われます。
当レポートでは、世界の注意欠陥多動性障害治療薬市場について調査し、市場の概要とともに、薬剤タイプ別、年齢群別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。Global Attention deficit hyperactivity disorder drug market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) by Age Group (Children and Adults), and Forecast (2020-2026)
The global attention deficit hyperactivity disorder drug market is anticipated to grow at a considerable CAGR during the forecast period. The increase in the number of pre-term deliveries of newborns is contributing the growth of the global attention deficit hyperactivity disorder drug market. According to the University of Maryland Medical Center (UMMC), this disease affects 20% of prematurely born babies currently. Governments across the globe are paying attention to the growing number of people suffering from a number of psychological disorders, including attention deficit hyperactivity disorder (ADHD). This focus of government towards treatment of such disease is further likely to drive the global market.
The global attention deficit hyperactivity disorder drug market is segmented based on drug type, distribution channel, and age group. Based on drug type, the attention deficit hyperactivity disorder drug market is segmented into stimulants and non- stimulants. Based on distribution channel, the attention deficit hyperactivity disorder drug market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. Based on age group, the attention deficit hyperactivity disorder drug market is segmented into children and adults.
Geographically, the global attention deficit hyperactivity disorder drug market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. Some of the companies operating in the global attention deficit hyperactivity disorder drug market include Pfizer Inc., Eli Lilly and Company., Novartis AG., GlaxoSmithKline PLC., Mallinckrodt Pharmaceuticals., Hisamitsu Pharmaceutical Co., Inc., and Johnson & Johnson., among others.
Market Segmentation
The Report Covers